Understanding and predicting lethal prostate cancer using advanced AI techniques
Dissecting and Predicting Lethal Prostate Cancer using Biologically Informed Artificial Intelligence
This study is looking to help men with intermediate and high-risk localized prostate cancer by using advanced technology to better understand their unique cancer traits, so doctors can make more personalized treatment choices that improve outcomes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10916204 on NIH RePORTER |
What this research studies
This research focuses on improving treatment strategies for patients with intermediate and high-risk localized prostate cancer by utilizing advanced artificial intelligence. It aims to analyze various molecular factors, including DNA repair gene alterations and transcriptional biomarkers, to better predict patient outcomes. By integrating complex molecular data with digital histopathology, the study seeks to develop more accurate predictive models that can guide personalized treatment decisions. The research leverages large patient cohorts and innovative computational methods to enhance the understanding of how these molecular features influence cancer aggressiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with intermediate to high-risk localized prostate cancer.
Not a fit: Patients with low-risk prostate cancer or those who have already undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment options for patients with prostate cancer.
How similar studies have performed: Previous research has shown promise in using AI and molecular data to improve cancer treatment outcomes, indicating that this approach has potential for success.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Van Allen, Eliezer M — Dana-Farber Cancer Inst
- Study coordinator: Van Allen, Eliezer M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.